Novel Vaccine AdjuvantsView this Special Issue
Research Article | Open Access
CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN- Responses
For the induction of robust humoral and cellular immune responses, a strong rationale exists to use vaccine-adjuvant combinations possessing both immune modulatory and enhanced delivery capabilities. Herein, we evaluated the combination of 2 different adjuvants, a TLR9 agonist, composed of synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG), and ISCOMATRIX adjuvant (ISCOMATRIX), composed of saponin, phospholipid, and cholesterol, which possesses both immunostimulatory and delivery properties. While both individual adjuvants have been shown effective in numerous preclinical and clinical studies, it is likely that for optimal adjuvant activity a combined adjuvant approach will be necessary. Herein, using three different antigens, namely, hepatitis B surface antigen (HBsAg), ovalbumin (OVA), and influenza A haemagglutinin antigen (HA), we show in mice that some adjuvant effects of CpG and ISCOMATRIX are further enhanced if they are used in combination. In particular, with all three antigens, IFN- levels were greatly increased with the CpG/ISCOMATRIX combination. The ability of the CpG/ISCOMATRIX combination to induce antitumor responses when administered with OVA following administration to mice of a highly metastatic OVA-secreting tumor cell line (B16-OVA melanoma) was also demonstrated. Thus the CpG/ISCOMATRIX combination may prove to be a valuable tool in the development of novel or improved vaccines.
A major impediment in the development of novel vaccines has been the lack of safe yet effective vaccine adjuvants. In recent years, synthetic oligodeoxynucleotides containing CpG motifs (CpG) have gained considerable interest as vaccine adjuvants owing to their inherent ability to induce and enhance Th1-type immunity. Through their direct interaction with Toll-like receptor 9 (TLR9) on human B cells and dendritic cells (DC), as well as indirect effects on other immune cells such as monocytes, macrophages, and T cells, CpG enhance antigen presentation and induce the production of high levels of Th1 cytokines, resulting in the production of potent antigen-specific Th1-type immune responses . CpG have been shown to enhance both humoral and cellular immunity are multiple species including humans [2–11]. These effects can be further enhanced if CpG are used in combination with other adjuvants possessing either immunomodulatory activity (e.g., QS21) [12, 13] or antigen delivery capability (e.g., liposomes and emulsions) [12, 14, 15]. Therefore, a combinatorial approach may be required to stimulate even stronger immune responses (in particular Th1-biased immunity) and, in the case of CpG as adjuvant, optimal adjuvanticity may be obtained if CpG is combined with another adjuvant possessing both immunomodulatory and enhanced delivery capabilities. This may be particularly true for effective control of cancer and chronic viral infection, where strong, broad, and multispecific Th1-type responses are required involving both CD4+ and CD8+T cell responses that depend on the induction of IFN-γ.
Herein, we evaluated the combination of CpG with ISCOMATRIX adjuvant (ISCOMATRIX). ISCOMATRIX is composed of ISCOPREP saponin (purified fraction of Quillaja saponin), cholesterol, and phospholipid and possesses both immunomodulatory and antigen delivery capabilities. ISCOMATRIX can induce strong humoral and cellular immune responses in both cancer and chronic infectious disease vaccines in multiple species including humans [16–20]. ISCOMATRIX has a broad range of effects including enhancement of antigen delivery and facilitation of antigen presentation to antigen-presenting cells such as DCs, induction of DC maturation, recruitment of immune cells to the draining lymph nodes via cytokine and chemokine induction, and activation of both innate and adaptive immune systems [16, 21, 22].
The CpG/ISCOMATRIX combination was evaluated using 3 different antigens: hepatitis B surface antigen (HBsAg), chicken egg ovalbumin (OVA), and influenza haemagglutinin antigen (HA) and compared to either adjuvant alone. We also tested whether the CpG/ISCOMATRIX combination could induce antitumor responses when administered with OVA following administration to mice of a highly metastatic OVA-secreting tumor cell line (B16-OVA melanoma).
2. Materials and Methods
HBsAg (recombinant protein from Saccharomyces cerevisiae, Seradyne, Indianapolis, IN), OVA (grade VII, Sigma-Aldrich, Saint Louis, MO), and HA (Texas 1/77 H3N2, from embryonated chicken eggs, Microbix Biosystems, Toronto, ON, Canada) were used.
B Class CpG ODN with nuclease-resistant phosphorothioate backbone (Pfizer, Langenfeld, Germany) was used. ISCOMATRIX adjuvant (ISCOMATRIX) composed of ISCOPREP saponin (purified fraction from bark extract of the Quillaja saponaria tree), dipalmitoyl phosphatidylcholine, and cholesterol (CSL Limited, Victoria, Australia) was used. ISCOMATRIX and ISCOPREP are registered trademarks of ISCOTEC AB, a CSL company. Aluminum hydroxide (alum) was used in the form of Alhydrogel “85,” which was obtained from Brenntag Biosector (Denmark).
Female BALB/c mice (6–8 wk; /group) were used with HBsAg and HA, whereas female C57Bl/6 mice (6–8 wk; /group) were used with OVA. All vaccine formulations were made up to a total volume of 50 μL with phosphate-buffered saline (PBS; Sigma Chemical Co., Saint Louis, MO) and administered by intramuscular (IM) injection in the left tibialis anterior (TA) muscle of mice lightly anaesthetized with Isoflurane (CDMV, Saint Hyacinthe, QC). Mice were immunized on days 0 and 28 with 1 μg HBsAg, on days 0, 14, and 21 with 10 μg OVA, or by a single immunization of 1 μg HA. Antigens were administered alone or in combination with adjuvants. CpG, ISCOMATRIX, and alum were used at doses of 10, 1, and 25 μg, respectively, whether used alone or in combination. Mouse strains, antigen, and adjuvant doses for each antigen were determined to be optimal based on previous studies conducted in our laboratories. All animal experiments were repeated on at least one independent occasion to ensure reproducibility of results.
2.4. Immune Assays
Animals were bled at various timepoints after immunization and antigen-specific total IgG, IgG1, and IgG2a (HBsAg and HA groups) or IgG2c (OVA groups) were measured in plasma by endpoint ELISA (in triplicate) for individual animals based on methods previously described , using 96-well plates coated with HBsAg (0.1 μg/well), OVA (1 μg/well), or HA (0.5 μg/well). Spleens were removed aseptically and antigen-specific cytotoxic T lymphocyte (CTL) activity was measured (HBsAg and OVA groups) as previously described . For this assay, lymphocytes were restimulated with irradiated murine cell line expressing HBsAg (P815/S) and OVA (EG7) for HBsAg and OVA immunized mice, respectively, or with nonantigen-expressing cells as controls.
IFN-γ secretion was measured in culture supernatants from antigen-restimulated splenocytes, obtained using HBsAg (5.0 μg/mL), OVA (0.5 mg/mL), or HA (5.0 μg/mL) as antigen-specific stimulants, either by ELISA (for HBsAg, OVA, and HA) as previously described  or by ELISPOT assay (for OVA). ELISPOT assay for IFN-γ used biotinylated antibodies, BD ELISPOT, as described by the manufacturer. IL-4 secretion was also measured by ELISA for HBsAg and HA antigens in culture supernatants taken at 24 hr using a commercially available kit (mouse IL-4 OpEIA; PharMingen, Mississauga, ON).
2.5. Murine Tumor Challenge Studies
To establish tumors, C57Bl/6 mice (/group) received 5 × 105 live B16 melanoma cells expressing OVA (Dr. John Frelinger and Dr. Edith Lord; University of Rochester, NY) by IV injection. In this model B16-OVA cells metastasize rapidly to the lungs and then to other major organs typically resulting in death of the untreated animal within 30 days after tumor induction. Animals injected with PBS (unimmunized) were used as placebo controls. On days 7 and 14 after tumor challenge, mice were immunized with 50 μg OVA alone or in combination with CpG, ISCOMATRIX, or the CpG/ISCOMATRIX combination. Five animals per group were euthanized 21 days after tumor induction to assess tumor burden and immunological readouts. Lungs were removed and metastases were counted manually using a dissecting microscope. The remaining animals were monitored for long-term survival.
All animal studies were conducted under approval of local Institutional Animal Care and Use Committees and in accordance with the guidelines of the Canadian Council on Animal Care (CCAC).
2.6. Statistical Analysis
Data were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA). Statistical significance of the difference between the two groups was calculated by Student’s 2-tailed t-test and between three or more groups by 1-factor analysis of variance (ANOVA) followed by post hoc analysis. Survival times following tumor challenges were compared using Kaplan-Meier curves and the log-rank (Mandel-Cox) test. Differences were considered to be not significant with .
3.1. Effect of Different Adjuvants on Antigen-Specific Plasma IgG
With all 3 antigens tested, antigen alone induced only low levels of Ag-specific IgG, even after boosting (Figures 1, 2, and 3). In contrast, the addition of either CpG or ISCOMATRIX significantly increased Ag-specific IgG levels (). With HBsAg (Figure 1) or OVA (Figure 2), levels of Ag-specific IgG were significantly higher with the CpG/ISCOMATRIX combination than with either adjuvant alone (). With HA (Figure 3), antibody levels with the CpG/ISCOMATRIX combination were higher than with ISCOMATRIX alone () but equivalent to those with CpG alone (). This may have been due to the single immunization typically used with HA compared to prime/boost regimen with HBsAg and OVA. When IgG isotypes were measured as an indication of Th bias of responses (IgG2a or 2c indicative of Th1 and IgG1 indicative of Th2), IgG responses were predominantly Th1 biased with CpG, whether alone or combined with ISCOMATRIX. With ISCOMATRIX alone, the IgG2/IgG1 ratio was different for each antigen, indicating that antigen itself can play a role in determining Th bias of immune responses (Figures 1, 2, and 3).
3.2. Effect of Different Adjuvants on Antigen-Specific CTL Activity
Only very low CTL activity was measured with HBsAg or OVA alone (Figure 4). With single adjuvants, CpG induced strong CTL activity with both antigens ( compared to Ag alone), whereas ISCOMATRIX induced strong CTL activity with HBsAg but not with OVA ( and , resp.). The CpG/ISCOMATRIX combination further augmented CTL responses compared to either adjuvant alone with HBsAg (e.g., at E : T of 50 : 1) but not with OVA ().
Overall, CTL activity was lower with OVA antigen compared to HBsAg. HBsAg, a virus-like particle, can use alternate MHC1 presentation pathways that could result in more CD8+ IFN-γ-producing cells than would be produced with a soluble protein such as OVA. While our results suggest this may be the case, it was not within the scope of the current study to further investigate this. Responses were shown to be antigen specific, since only very low CTL activity was measured in samples that were stimulated with control cells which did not express antigen (results not shown).
3.3. Effect of Different Adjuvants on Antigen-Specific IFN-γ Secretion
Only very low levels of IFN-γ were detected in supernatants from mice immunized using antigen alone (Figure 5). CpG alone enhanced IFN-γ levels with both HBsAg and OVA () but not with HA, whereas ISCOMATRIX alone induced only low levels of IFN-γ with all three antigens. The CpG/ISCOMATRIX combination enhanced IFN-γ secretion with all three antigens (), although there was a particularly strong synergy with HBsAg and HA which had IFN-γ concentrations 20- to 30-fold higher than with CpG or ISCOMATRIX alone (). For example, using HBsAg as an antigen, mean IFN-γ levels were approximately 2600, 400, and 70000 pg/mL with CpG, ISCOMATRIX, or the CpG/ISCOMATRIX combination, respectively, indicative of a synergistic rather than additive effect (Figure 5(a)). Likewise, using HA as an antigen, mean IFN-γ levels were approximately 125, 100, and 5000 pg/mL with CpG, ISCOMATRIX, or the CpG/ISCOMATRIX combination, respectively, (Figure 5(c)). Two different methods of measuring IFN-γ were employed (i.e., ELISA or ELISPOT) due to reagent availability at the time of each study; however, data obtained with different assays were not directly compared. Nevertheless, with both methods a strong synergy in IFN-γ secretion was observed with the CpG/ISCOMATRIX combination compared to either adjuvant alone. Responses were shown to be antigen specific, since only low levels of IFN-γ were obtained in samples that were not stimulated with antigen (results not shown). For all experiments, IFN-γ levels in response to ConA stimulation were equivalently strong (data not shown).
Only very low levels of IL-4 were detected in supernatants from mice immunized using any of the antigens and there was no increase seen in the presence of adjuvants (data not shown).
3.4. Evaluation of Different Adjuvants in B-16 Melanoma Model
On day 21 after tumor induction, five animals from each treatment group were euthanized, and IFN-γ secretion was measured following antigen restimulation of splenocytes. Only very low levels of IFN-γ were detected in supernatants from mice immunized using OVA alone (Figure 6(a)). Both CpG and ISCOMATRIX alone enhanced IFN-γ secretion compared to antigen alone (), with significantly higher levels of IFN-γ obtained in supernatants from mice immunized using CpG alone as an adjuvant compared to ISCOMATRIX alone (). Significantly higher levels of IFN-γ were obtained in supernatants from mice immunized using the CpG/ISCOMATRIX combination compared to when either was used alone ().
3.5. Effect of CpG/ISCOMATRIX Adjuvant Combination on Survival and Metastasis
The effect of immunization on survival and lung metastasis was measured following administration of the murine tumor model, B16-OVA melanoma. All nonimmunized control animals died or were euthanized for humane reasons by day 33 after inoculation of tumor cells (Figure 6(b)), and upon necropsy all control animals were found to have developed extensive lung metastases which were too numerous to count (>300) (data not shown). Immunization of animals with OVA alone did not significantly enhance survival or reduce metastasis compared to control animals (), such that by day 40 all animals had died or were euthanized for humane purposes. Immunization using CpG or ISCOMATRIX alone significantly enhanced survival and reduced metastasis over OVA alone or placebo controls () (Figure 6). Median survival time was 30 days for unimmunized control animals and 29, 42, 42, and 45 days for animals immunized with OVA alone, OVA + CpG, OVA + ISCOMATRIX, or OVA + CpG/ISCOMATRIX combination, respectively. Therefore, for example, on day 40 when 100% of animals immunized with antigen alone had succumbed to disease, mortality was only 0 to 20% for animals immunized using ISCOMATRIX, CpG, or the CpG/ISCOMATRIX, with no significant differences in longevity between these groups. Although all animals in these groups eventually succumbed to disease, those immunized with OVA and CpG/ISCOMATRIX combination had significantly reduced lung metastasis compared to either adjuvant alone () (Figure 6(c)).
3.6. Comparison of Effects of CpG/ISCOMATIX and CpG/Alum Adjuvant Combinations on HBsAg-Specific IFN-γ Secretion
The CpG/ISCOMATRIX adjuvant combination enhanced HBsAg-specific IFN-γ secretion compared to either adjuvant alone (), whereas levels obtained with CpG/alum were equivalent to those obtained with CpG alone (). Mean IFN-γ levels obtained with the CpG/ISCOMATRIX combination were approximately 15-fold higher than those obtained with the CpG/alum adjuvant combination (Figure 7).
For the development of effective antitumor or antiviral disease vaccines, strong immune adjuvants are required to induce robust immune responses. Herein, we have compared CpG with ISCOMATRIX using different antigens and adjuvant combinations. We have shown that both CpG and ISCOMATRIX are strong adjuvants when used alone, which was not surprising, as both CpG and ISCOMATRIX have successfully been used as adjuvants in multiple species, including humans [16, 25]. The strong adjuvanticity associated with CpG and ISCOMATRIX could be further enhanced when used in combination. In particular, a strong synergy was seen in IFN-γ secretion with all three antigens despite the fact that different immunization protocols were used with each antigen. Overall, the strongest synergy was seen with HBsAg which had the longest time interval between doses (4 weeks). Since immunization schedule can impact both strength and nature of induced responses, it is possible that responses with OVA and HA as antigens could be further improved with either an increased time interval between doses (OVA) or an increased number of doses (HA).
The strong adjuvanticity seen in this study associated with the combination of CpG and ISCOMATRIX is in line with previous reports in mice using immunostimulatory complexes (ISCOMs). For example, immunization with inactivated Francisella tularensis live vaccine strain (LVS) adjuvanted with CpG combined with preformed ISCOMs provided better protection than an alum-adjuvanted vaccine when challenged with a virulent strain of F. tularensis [26, 27]. Also, immunization with cytomegalovirus (CMV) glycoprotein B vaccine formulated with CpG and ISCOMs elicited strong CMV-specific immunity against multiple CMV strains . To evaluate whether the strong synergy between CpG and ISCOMATRIX seen in immunological readouts would translate to better functionality, we also evaluated the CpG/ISCOMATRIX combination in a therapeutic metastatic lung carcinoma model. In this model, the CpG/ISCOMATRIX combination also induced significantly higher levels of OVA-specific IFN-γ secretion compared to either adjuvant alone, and this translated into a reduction in lung metastases in these animals. However, despite the strong antitumor immune responses, all animals eventually succumbed to the cancer. It is possible that the kinetics and/or strength of the immune response were not optimal or fast enough to curtail an already established tumor, that an immune response against a single tumor antigen is not sufficient to control tumor growth, or that although we could measure OVA-specific T cell responses ex vivo, these cells may have been rendered inactive at the site of the tumor by immune suppressive mechanisms induced by the tumor. Nevertheless, although there was no long-term survival benefit, the CpG/ISCOMATRIX combination did help induce strong enough immune responses to significantly reduce lung metastasis in this aggressive tumor model.
Similar results have been demonstrated in a murine pancreatic carcinoma model, whereby the inclusion of CpG in an ISCOM-based vaccine was shown to reduce numbers of regulatory T cells, enhance CTL responses, and induce regression of pancreatic tumors . It is possible that we would have seen a stronger synergy in our tumor challenge studies with additional boosts or a different immunization schedule; however, the very aggressive nature of this tumor model made this difficult to evaluate. It should also be noted that the adjuvant dose when used in combination was not optimized but rather used at the optimal dose for each adjuvant alone. It is possible that changing the dose of either adjuvant may produce better responses as shown in the pancreatic carcinoma studies. There are almost endless combinations of doses that are possible and doing such studies in mouse models is of limited value as the optimal human dose for each adjuvant alone is quite different from that in mice.
The increased immunogenicity seen with the CpG/ISCOMATRIX combination is likely due to the immunomodulatory properties of the adjuvant mixture as well as enhanced delivery and/or protection from degradation of the CpG by ISCOMATRIX. Indeed, for optimal synergy between CpG and ISCOMATRIX both the delivery components (phospholipids and cholesterol) and immunomodulatory components (ISCOPREP saponin) of ISCOMATRIX are required, since when CpG were combined with ISCOPREP saponin alone, although stronger secretion of IFN-γ was observed than with either adjuvant alone, levels of IFN-γ were lower than those observed with the CpG/ISCOMATRIX combination (data not shown). Although the exact mechanism of action of ISCOMATRIX has not yet been fully elucidated, it has recently been shown to combine both immune activation as well as enhanced antigen delivery to DCs leading to an effective cross-priming ofCD8+T cells [21, 30]. The uptake of antigen when formulated with ISCOMATRIX by DCs occurs via endocytosis with delivery of antigen to lysosomes and subsequent rapid translocation to the cytosol resulting in enhanced Ag cross-presentation . It is possible that this efficiency of delivery to the endosome of molecules also applies to CpG and may play a role in the strong synergy seen with the combination, since the CpG receptor TLR9 is located in the endosomal compartment , and CpG-mediated activation of this receptor can enhance antigen cross-presentation . The direct delivery of substances to the endosome is likely critical to the strong synergistic effect seen with the CpG/ISCOMATRIX combination, since alum, another delivery system, failed to achieve the same result.
Therefore, the significant enhancement in antigen-specific IFNγ secretion observed with the CpG/ISCOMARIX combination may result from enhanced antigen cross-presentation mediated by both adjuvants. It is also known that both adjuvants activate innate immune cells and so a combined effect may lead to a much more optimal local environment for the adaptive immune response to occur. As ISCOMATRIX does not contain TLR ligands it is highly unlikely that it signals through TLRs as supported by a number of in vitro studies (data not shown). It has been shown, however, that the MyD88 signaling pathway is important for the induction of strong IFN+ CD8+ T cell responses with ISCOMATRIX vaccines so there does appear to be some overlap with CpG signaling pathways .
Ultimately, as with all animal studies, limitations exist for extrapolation in humans and it remains to be determined whether CpG and ISCOMATRIX will prove to be a useful adjuvant combination in the clinic. It is possible that activity in humans may be less than in mice, due to differences in TLR9 expression in human and mouse dendritic cell populations, although a number of studies have now shown that CpG are still active in higher species, including humans.
The studies presented herein highlight that the rational combination of different adjuvants could lead to the development of novel vaccines or the enhancement of existing vaccines. Vaccination strategies that include both CpG and ISCOMATRIX are one means by which the strong Th1 immune responses required to prevent and treat chronic infection and tumors may be achieved.
- M. J. McCluskie and A. M. Krieg, “Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA,” Current Topics in Microbiology and Immunology, vol. 311, pp. 155–178, 2006.
- O. S. Segaard, N. Lohse, Z. B. Harboe et al., “Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial,” Clinical Infectious Diseases, vol. 51, no. 1, pp. 42–50, 2010.
- I. Sagara, R. D. Ellis, A. Dicko et al., “A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults,” Vaccine, vol. 27, no. 52, pp. 7292–7298, 2009.
- D. Rynkiewicz, M. Rathkopf, I. Sim et al., “Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers,” Vaccine, vol. 29, no. 37, pp. 6313–6320, 2011.
- G. E. D. Mullen, R. D. Ellis, K. Miura et al., “Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria,” PLoS ONE, vol. 3, no. 8, article e2940, 2008.
- S. A. Halperin, G. van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden, “A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant,” Vaccine, vol. 21, no. 19-20, pp. 2461–2467, 2003.
- R. D. Ellis, G. E. D. Mullen, M. Pierce et al., “A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals,” Vaccine, vol. 27, no. 31, pp. 4104–4109, 2009.
- C. L. Cooper, H. L. Davis, M. L. Morris et al., “CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study,” Journal of Clinical Immunology, vol. 24, no. 6, pp. 693–701, 2004.
- C. L. Cooper, H. L. Davis, M. L. Morris et al., “Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine,” Vaccine, vol. 22, no. 23-24, pp. 3136–3143, 2004.
- C. L. Cooper, H. L. Davis, J. B. Angel et al., “CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults,” AIDS, vol. 19, no. 14, pp. 1473–1479, 2005.
- C. L. Cooper, J. B. Angel, I. Seguin, H. L. Davis, and D. W. Cameron, “CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years,” Clinical Infectious Diseases, vol. 46, no. 8, pp. 1310–1314, 2008.
- R. D. Weeratna, M. J. McCluskie, Y. Xu, and H. L. Davis, “CpG DNA induces stronger immune responses with less toxicity than other adjuvants,” Vaccine, vol. 18, no. 17, pp. 1755–1762, 2000.
- S. K. Kim, G. Ragupathi, S. Cappello, E. Kagan, and P. O. Livingston, “Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates,” Vaccine, vol. 19, no. 4-5, pp. 530–537, 2000.
- D. T. O'Hagan, M. Singh, J. Kazzaz et al., “Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen,” Vaccine, vol. 20, no. 27-28, pp. 3389–3398, 2002.
- W. M. Li, W. H. Dragowska, M. B. Bally, and M. P. Schutze-Redelmeier, “Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes,” Vaccine, vol. 21, no. 23, pp. 3319–3329, 2003.
- E. Maraskovsky, M. Schnurr, N. S. Wilson, N. C. Robson, J. Boyle, and D. Drane, “Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant,” Immunology and Cell Biology, vol. 87, no. 5, pp. 371–376, 2009.
- I. D. Davis, W. Chen, H. Jackson et al., “Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10697–10702, 2004.
- T. Nicholaou, L. M. Ebert, I. D. Davis et al., “Regulatory T-Cell-mediated attenuation of T-Cell responses to the NY-ESO-1ISCOMATRIX vaccine in patients with advanced malignant melanoma,” Clinical Cancer Research, vol. 15, no. 6, pp. 2166–2173, 2009.
- I. H. Frazer, M. Quinn, J. L. Nicklin et al., “Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia,” Vaccine, vol. 23, no. 2, pp. 172–181, 2004.
- D. Drane, E. Maraskovsky, R. Gibson et al., “Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers,” Human Vaccines, vol. 5, no. 3, pp. 151–157, 2009.
- P. Duewell, U. Kisser, K. Heckelsmiller et al., “ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells,” Journal of Immunology, vol. 187, no. 1, pp. 55–63, 2011.
- N. S. Wilson, B. Yang, A. B. Morelli et al., “ISCOMATRIX vaccines mediate CD8(+) T-cell cross-priming by a MyD88-dependent signaling pathway,” Immunology and Cell Biology, vol. 90, no. 5, pp. 540–552, 2012.
- H. L. Davis, R. Weeranta, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg, “CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen,” Journal of Immunology, vol. 160, no. 2, pp. 870–876, 1998.
- R. D. Weeratna, S. R. Makinen, M. J. McCluskie, and H. L. Davis, “TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848),” Vaccine, vol. 23, no. 45, pp. 5263–5270, 2005.
- C. Bode, G. Zhao, F. Steinhagen, T. Kinjo, and D. M. Klinman, “CpG DNA as a vaccine adjuvant,” Expert Review of Vaccines, vol. 10, no. 4, pp. 499–511, 2011.
- J. E. Eyles, M. G. Hartley, T. R. Laws, P. C. F. Oyston, K. F. Griffin, and R. W. Titball, “Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS),” Microbial Pathogenesis, vol. 44, no. 2, pp. 164–168, 2008.
- J. E. Eyles, B. Unal, M. G. Hartley et al., “Immunodominant Francisella tularensis antigens identified using proteome microarray,” Proteomics, vol. 7, no. 13, pp. 2172–2183, 2007.
- V. Dasari, C. Smith, J. Zhong, G. Scott, W. Rawlinson, and R. Khanna, “Recombinant glycoprotein B vaccine formulation with toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus,” Journal of General Virology, vol. 92, no. 5, pp. 1021–1031, 2011.
- C. Jacobs, P. Duewell, K. Heckelsmiller et al., “An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma,” International Journal of Cancer, vol. 128, no. 4, pp. 897–907, 2011.
- M. Schnurr, M. Orban, N. C. Robson et al., “ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II,” Journal of Immunology, vol. 182, no. 3, pp. 1253–1259, 2009.
- P. Ahmad-Nejad, H. Hacker, M. Rutz, S. Bauer, R. M. Vabulas, and H. Wagner, “Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments,” European Journal of Immunology, vol. 32, no. 7, pp. 1958–1968, 2002.
- T. Maurer, A. Heit, H. Hochrein et al., “CpG-DNA aided cross-presentation of soluble antigens by dendritic cells,” European Journal of Immunology, vol. 32, no. 8, pp. 2356–2364, 2002.
Copyright © 2013 Michael J. McCluskie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.